BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20602231)

  • 1. Differential gene expression in acute lymphoblastic leukemia cells surviving allogeneic transplant.
    Shand JC; Jansson J; Hsu YC; Campbell A; Mullen CA
    Cancer Immunol Immunother; 2010 Nov; 59(11):1633-44. PubMed ID: 20602231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.
    Young FM; Campbell A; Emo KL; Jansson J; Wang PY; Jordan CT; Mullen CA
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):622-30. PubMed ID: 18489987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of B cell immune responses to acute lymphoblastic leukemia in murine allogeneic hematopoietic stem cell transplantation recipients treated with donor lymphocyte infusion and/or vaccination.
    Mullen CA; Campbell A; Tkachenko O; Jansson J; Hsu YC
    Biol Blood Marrow Transplant; 2011 Feb; 17(2):226-38. PubMed ID: 20831897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype.
    Castro FV; McGinn OJ; Krishnan S; Marinov G; Li J; Rutkowski AJ; Elkord E; Burt DJ; Holland M; Vaghjiani R; Gallego A; Saha V; Stern PL
    Leukemia; 2012 Jul; 26(7):1487-98. PubMed ID: 22266911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minor antigen distribution predicts site-specific graft-versus-tumor activity of adoptively transferred, minor antigen-specific CD8 T Cells.
    Shand JC; Qin H; Nasholm N; Capitini CM; Fry TJ
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):26-36. PubMed ID: 24141010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-protective murine graft-versus-leukemia responses to phenotypically distinct myeloid leukemia lines.
    Patterson AE; Korngold R
    Biol Blood Marrow Transplant; 2000; 6(5A):537-47. PubMed ID: 11071259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.
    Oostvogels R; Minnema MC; van Elk M; Spaapen RM; te Raa GD; Giovannone B; Buijs A; van Baarle D; Kater AP; Griffioen M; Spierings E; Lokhorst HM; Mutis T
    Leukemia; 2013 Mar; 27(3):642-9. PubMed ID: 23079962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between enhancement of graft-versus-leukemia effects following allogeneic bone marrow transplantation by rIL-2 and increased frequency of cytotoxic T-lymphocyte precursors in murine myeloid leukemia.
    Leshem B; Vourka-Karussis U; Slavin S
    Cytokines Cell Mol Ther; 2000 Sep; 6(3):141-7. PubMed ID: 11140883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient expansion of Mac1+Ly6-G+Ly6-C+ early myeloid cells with suppressor activity in spleens of murine radiation marrow chimeras: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions.
    Billiau AD; Fevery S; Rutgeerts O; Landuyt W; Waer M
    Blood; 2003 Jul; 102(2):740-8. PubMed ID: 12676788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute lymphoblastic leukemia cells that survive combination chemotherapy in vivo remain sensitive to allogeneic immune effects.
    Jansson J; Hsu YC; Kuzin II; Campbell A; Mullen CA
    Leuk Res; 2011 Jun; 35(6):800-7. PubMed ID: 21074852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation.
    Drobyski WR; Gendelman M; Vodanovic-Jankovic S; Gorski J
    J Immunol; 2003 Mar; 170(6):3046-53. PubMed ID: 12626559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation.
    Stölzel F; Hackmann K; Kuithan F; Mohr B; Füssel M; Oelschlägel U; Thiede C; Röllig C; Platzbecker U; Schetelig J; Illmer T; Schaich M; Seliger B; Hartmann A; Baretton G; Zietz C; Ehninger G; Schrock E; Bornhäuser M
    Transplantation; 2012 Apr; 93(7):744-9. PubMed ID: 22314337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
    Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
    Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model).
    Azar Y; Shainer R; Almogi-Hazan O; Bringer R; Compton SR; Paidas MJ; Barnea ER; Or R
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):519-28. PubMed ID: 23266739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.
    Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P
    Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Separation of antileukemic effects from graft-versus-host disease in MHC-haploidentical murine bone marrow transplantation: participation of host immune cells.
    Satake A; Inoue T; Kubo S; Taniguchi Y; Imado T; Fujioka T; Horiuchi M; Xu Y; Ikegame K; Yoshihara S; Kaida K; Tamaki H; Okada M; Okamura H; Ogawa H
    Int J Hematol; 2010 Apr; 91(3):485-97. PubMed ID: 20300982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
    Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity.
    Lu Y; Giver CR; Sharma A; Li JM; Darlak KA; Owens LM; Roback JD; Galipeau J; Waller EK
    Blood; 2012 Jan; 119(4):1075-85. PubMed ID: 22130799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.